Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 85,874 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 1 Clear all

Conditions: Influenza
Interventions: Synbiotic AKSB; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 65 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Eating Disorders, Anorexia Nervosa, Bulimia Nervosa, Binge Eating Disorder, Other Specified Feeding or Eating Disorder
Interventions: Eating Disorder Dynamic Intervention; Behavioral
Lead sponsor: Trustees of Dartmouth College; Other
Eligibility: 18 Years to 70 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Smoking, Alcoholism
Interventions: Cognitive Behavior Therapy for alcohol and smoking cessation, Nicoderm CQ nicotine patch, Placebo gum, Nicotine gum - Nicorette®; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Newington, Connecticut

Conditions: Atopic Dermatitis
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 26
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 21 more

Conditions: Solid Tumors, Breast Cancer
Interventions: Tanespimycin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Scottsdale, Arizona • Tucson, Arizona • New York, New York

Conditions: Nicotine Dependence, Other Tobacco Product
Interventions: Nicotine, Low Dose Menthol, High Dose Menthol; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 20 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cocaine Dependence
Interventions: Baclofen ER, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
Interventions: Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101; Drug · Radiation
Lead sponsor: Robert Lowsky; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Aliskiren, Irbesartan, Captopril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasms, Colorectal
Interventions: lapatinib, oxaliplatin, capecitabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Symptomatic Femoro-popliteal Chronic Total Occlusion
Interventions: TruePath CTO Device, CROSSER CTO Device; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Tinnitus
Interventions: Brexanolone; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 2
States / cities: Atlanta, Georgia • Iowa City, Iowa

Conditions: Sleep
Interventions: Sleep Study Product Usage; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 1,750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Major Depressive Disorder
Interventions: Ketamine, Saline, Magnetic Resonance Imaging (MRI); Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Injuries, Patellofemoral Pain Syndrome, Iliotibial Band Syndrome
Interventions: Strength and Coordination Training, Walking; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Osteosarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions: sorafenib tosylate, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study, computed tomography, dynamic contrast-enhanced magnetic resonance imaging; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cataract
Interventions: Vitrax II, Viscoat; Device
Lead sponsor: Abbott Medical Optics; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Santa Ana, California

Conditions: Breast Cancer, Mastectomy, Perfusion; Complications, Hemostasis
Interventions: PlasmaBlade 3.0S; Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Nemtabrutinib, Efavirenz; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hepatic Impairment (HI)
Interventions: EDG-7500; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Breast Cancer
Interventions: Fulvestrant, Tamoxifen; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: New York, New York

Conditions: Advanced Solid Tumors
Interventions: Dalutrafusp alfa, mFOLFOX6 Regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Dallas, Texas + 1 more

Conditions: Adiposity
Interventions: Vitamin D3 (cholecalciferol), 2000 IU per day, omega-3 fatty acids (fish oil); Dietary Supplement · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 10 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly

Eating Disorder Dynamic Intervention

Combination Nicotine Replacement for Alcoholic Smokers

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1

A Study of Baclofen ER

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus

Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer

The Lumen Study: Comparing Devices for Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)

An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus

Radicle Sleep: A Study of Plant Derived Cannabinoids on Sleep and Overall Health Outcomes

Ketamine in the Treatment of Depression

Effect of Strength and Coordination Training on Biomechanics and Injury in New Runners

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)

Clinical Evaluation of a New Viscoelastic for Cataract Surgery

Post-Operative Outcomes of Low Thermal Dissection vs. Traditional Electrosurgery

A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

Study of Dalutrafusp Alfa (Formerly GS-1423) in Participants With Advanced Solid Tumors

Vitamin D and Omega-3 Adiposity Trial (VITAL Adiposity)

Clinical and Laboratory Analysis of Familial Cancer